In the current study, we demonstrate that UCK2 catalytically promotes HCC proliferation and non-catalytically enhances HCC metastasis by activating the EGFR-AKT pathway, which inspired us to design a combined drug treatment to simultaneously block the catalytic dependent and independent functions of UCK2. Here, UCK2 is linked to hepatocellular carcinoma.